Cargando…

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based on PD-L1 expression and the performance status assessed with the use of Eastern Cooperative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mojsak, Damian, Kuklińska, Beata, Dębczyński, Michał, Mróz, Robert Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063900/ https://www.ncbi.nlm.nih.gov/pubmed/33911982 http://dx.doi.org/10.5114/wo.2021.105031

Ejemplares similares

A 75-Year-Old Female Smoker with Advanced Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status 2 who Responded to Combination Immunochemotherapy with Atezolizumab, Etoposide, and Carboplatin
por: Dębczyński, Michał, et al.
Publicado: (2022)

The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports
por: Mojsak, Damian, et al.
Publicado: (2022)

Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis
por: Mojsak, Damian, et al.
Publicado: (2023)

ATP12A Proton Pump as an Emerging Therapeutic Target in Cystic Fibrosis and Other Respiratory Diseases
por: Dębczyński, Michał, et al.
Publicado: (2023)

Neuroinfection as a Mask of Lung Cancer: A Case Series
por: Kuklińska, Beata, et al.
Publicado: (2016)

Predicting survival in metastatic non‐small cell lung cancer patients with poor ECOG‐PS: A single‐arm prospective study
por: Cunha, Mateus Trinconi, et al.
Publicado: (2022)

Limited doses of immunotherapy use in advanced non‐small cell lung cancer elderly patients with ECOG of 2 and high PDL‐1 expression
por: Wong, Pui Yee, et al.
Publicado: (2021)

Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1
por: Caires-Lima, Rafael, et al.
Publicado: (2018)

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
por: Gridelli, C., et al.
Publicado: (2021)

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
por: Schneider, B P, et al.
Publicado: (2014)

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer
por: MICHAEL, M., et al.
Publicado: (2012)

The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer
por: Dolan, Ross D., et al.
Publicado: (2020)

Immunotherapy for Non-Small Cell Lung Cancer
por: Yoon, Sung Ho
Publicado: (2014)

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer
por: Forrest, L M, et al.
Publicado: (2004)

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
por: Langer, Corey J., et al.
Publicado: (2016)

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Huang, Lan, et al.
Publicado: (2020)

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
por: Bi, Nan, et al.
Publicado: (2020)

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer
por: Walker, Suzanne
Publicado: (2016)

Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020)

Validation of the Korean-Everyday Cognition (K-ECog)
por: Song, Minji, et al.
Publicado: (2019)

Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
por: Tsiouda, Theodora, et al.
Publicado: (2020)

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer
por: Zhang, Nan, et al.
Publicado: (2022)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Intracranial complete remissions in an aumolertinib-treated EGFR mutation-positive non-small cell lung cancer (NSCLC) patient with symptomatic brain metastases and Eastern Cooperative Oncology Group performance status (ECOG PS) up to 4: a case report
por: Shan, Xiu, et al.
Publicado: (2023)

A novel method for the identification of synchronization effects in multichannel ECoG with an application to epilepsy
por: Graef, A., et al.
Publicado: (2013)

Decoding Saccadic Directions Using Epidural ECoG in Non-Human Primates
por: Lee, Jeyeon, et al.
Publicado: (2017)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)

First line Immunotherapy for Non-Small Cell Lung Cancer
por: Nasser, Nicola J., et al.
Publicado: (2020)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Immunotherapy through the Lens of Non-Small Cell Lung Cancer
por: Stanley, Robyn, et al.
Publicado: (2023)

Self-Regulated Dynamical Criticality in Human ECoG
por: Solovey, Guillermo, et al.
Publicado: (2012)

Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
por: Adderley, H., et al.
Publicado: (2020)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u15tju76avulka6o7o3l12hceq